Summary of Collegium Pharmaceutical Conference Call Company Overview - **Company**: Collegium Pharmaceutical (NasdaqGS:COLL) - **Focus**: Chronic pain management and ADHD with five marketed products - **Revenue**: Expected to reach $780 million in 2025, representing a 24% year-over-year growth [1][3][11] Core Business Insights - **Flagship Products**: - Xtampza: Extended-release oxycodone with abuse-deterrent technology - Belbuca: Long-acting opioid using buprenorphine buccal film technology - Nucynta: Treats severe and persistent pain, including diabetic neuropathy - Jornay PM: Unique evening-dosed ADHD medication [2][3][11] - **Recent Acquisition**: IronSure in 2024, adding Jornay PM to the portfolio [2] Financial Performance - **Q3 2025 Results**: - Revenues: $209.4 million, up 31% year-over-year - Adjusted EBITDA: $133 million, up 27% year-over-year - Cash from operations: Nearly $80 million, total cash balance of $286 million [6][11] - **Debt Management**: - Net debt to adjusted EBITDA ratio down to 1.2 times, expected to be below 1 by year-end [7][12] Growth Strategy - **Three Core Pillars**: 1. Grow Jornay through strategic investments in sales and marketing 2. Maximize the value of the pain portfolio 3. Strategically deploy capital for business development, debt repayment, and share repurchases [4][12] - **Market Position**: - Jornay PM is the fastest-growing stimulant for ADHD, with a 20% growth in prescriptions [8][9] - Pain portfolio revenue growth: 10% for Belbuca and 2% for Xtampza in Q3 [11] Market Dynamics - **ADHD Market**: - Approximately 100 million prescriptions annually, with 90% being stimulant medications - Jornay PM has a unique evening dosing, leading to high differentiation and prescriber intent [7][8] - **Pain Management Market**: - Collegium's pain portfolio represents about half of the branded extended-release market - Minimal regulatory or clinical risks compared to peers [11][12] Shareholder Value - **Share Repurchases**: Over $220 million repurchased since 2021, with an authorization for an additional $150 million through 2026 [1][12] - **Future Outlook**: Confident in the strength and durability of the business, with robust revenue growth and strong cash flow generation expected [11][13]

Core Insights - Collegium Pharmaceutical, Inc. (COLL) is highlighted as a promising biopharma company, with a focus on its recent performance and potential investment opportunities [1]. Group 1: Company Overview - Collegium Pharmaceutical is being revisited for analysis after a previous article in March, indicating ongoing interest and developments in the company [1]. - The company is part of a model portfolio that includes 12-20 high upside biotech stocks, suggesting a strategic selection aimed at maximizing investor returns [1]. Group 2: Analyst Background - The analysis is led by an experienced market analyst with over 13 years in the biotech sector, specializing in high beta sectors that offer potentially large returns [1]. - The analyst is associated with The Biotech Forum, which provides live discussions on trade ideas and weekly updates on market commentary and portfolio performance [1].

Core Insights - Organon is set to announce its earnings results, with analysts expecting flat revenue year on year at $1.57 billion, a slowdown from the previous year's 4.1% increase [2] - Last quarter, Organon reported revenues of $1.59 billion, exceeding analysts' expectations by 2.8% and achieving a strong performance in terms of both revenue and EPS estimates [1][3] Revenue Expectations - Analysts have generally maintained their revenue estimates for Organon over the past 30 days, indicating a stable outlook heading into earnings [3] - The company has missed Wall Street's revenue estimates twice in the last two years, raising concerns about its performance consistency [3] Peer Performance - In the branded pharmaceuticals segment, peers like Eli Lilly and Collegium Pharmaceutical reported significant year-on-year revenue growth of 53.9% and 31.4%, respectively, both exceeding analysts' expectations [4] - Positive sentiment in the branded pharmaceuticals sector is reflected in an average share price increase of 3.9% over the last month, contrasting with Organon's decline of 29.4% during the same period [5] Analyst Sentiment - The average analyst price target for Organon is $10.83, while its current share price stands at $6.78, indicating potential upside if the company can meet or exceed expectations [5]

Core Insights - Collegium Pharmaceutical (COLL) reported quarterly earnings of $2.25 per share, exceeding the Zacks Consensus Estimate of $1.88 per share, and showing an increase from $1.61 per share a year ago, resulting in an earnings surprise of +19.68% [1][2] - The company achieved revenues of $209.36 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 10.35% and up from $159.3 million year-over-year [2] - Collegium Pharmaceutical shares have increased approximately 25.1% year-to-date, outperforming the S&P 500's gain of 15.6% [3] Earnings Outlook - The future performance of Collegium Pharmaceutical's stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.10 on revenues of $197.79 million, and for the current fiscal year, it is $7.08 on revenues of $753.27 million [7] Industry Context - The Medical - Drugs industry, to which Collegium Pharmaceutical belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Metagenomi (MGX), is expected to report a quarterly loss of $0.60 per share, reflecting a year-over-year decline of -33.3%, with revenues projected at $9.26 million, down 19.6% from the previous year [9]

Financial Data and Key Metrics Changes - The company reported record total revenues of $209.4 million, up 31% year-over-year [23] - Adjusted EBITDA reached $133 million, reflecting a 27% increase year-over-year [23] - Cash from operations was $78.4 million, with a cash balance of $285.9 million at the end of the quarter [25][23] - The company raised its 2025 financial guidance, expecting total product revenues in the range of $775 million to $785 million, representing a 24% increase year-over-year [25] Business Line Data and Key Metrics Changes - Jornay PM generated record net revenue of $41.8 million, with prescriptions growing 20% year-over-year [6][23] - The pain portfolio achieved record net revenue of $167.6 million, up 11% year-over-year [7] - Belbuca net revenue was $58.3 million, up 10% year-over-year, while Xtampza net revenue was $50.5 million, up 2% year-over-year [24] - Nucynta franchise net revenue reached $54.8 million, reflecting a 21% year-over-year increase [24] Market Data and Key Metrics Changes - Jornay PM's market share in the long-acting branded methylphenidate market grew to 23.4%, an increase of 6.3 percentage points year-over-year [14] - The prescriber base for Jornay PM reached an all-time high of 27,700, up 22% year-over-year [14] - The pediatric and adolescent segment, representing about 80% of total prescriptions, grew 18% year-over-year, while the adult segment grew 29% year-over-year [15] Company Strategy and Development Direction - The company is focused on driving significant growth for Jornay PM, maximizing the pain portfolio, and strategically deploying capital [9][10] - There is an emphasis on raising awareness of Jornay's differentiated profile among healthcare providers, patients, and caregivers [10] - The company remains active in pursuing additional differentiated medicines to expand its portfolio through business development [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability of the pain portfolio and significant growth from Jornay PM [8] - The company is committed to improving the lives of patients and creating value for shareholders [29] - Management highlighted the importance of ongoing investments in commercial efforts and the expansion of the sales force to drive future growth [10][11] Other Important Information - The company celebrated its 10-year anniversary as a publicly traded entity, marking a decade of delivering differentiated medicines [9] - The company presented nine posters at Pain Week 2025, showcasing real-world data from its pain portfolio [8] Q&A Session Summary Question: How did return reserves and inventory impact Q3 script growth? - Management noted that gross to net improved in Q3, with returns rates and favorable contracting contributing to this improvement [32] Question: What impact did the expanded sales force have in Q3? - Management indicated that while early signals of impact were observed, significant effects from the expanded sales force are expected in 2026 and beyond [33] Question: What is the adherence rate for Jornay PM since the back-to-school season? - Adherence rates for Jornay PM are consistent with typical ADHD medications, showing a standard adherence curve [44] Question: What is the company's approach to business development? - The company remains active in business development, focusing on commercial or near-commercial assets while balancing capital deployment strategies [53]

Q3 2025 Earnings Report November 6, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future ev ...

Financial Performance - Product revenues for Q3 2025 reached $209.4 million, a 31.5% increase from $159.3 million in Q3 2024[19] - Gross profit for the nine months ended September 30, 2025, was $334.9 million, compared to $279.1 million for the same period in 2024, reflecting a 19.9% increase[19] - Net income for Q3 2025 was $31.5 million, significantly up from $9.3 million in Q3 2024, representing a 237.5% increase[19] - The company reported a comprehensive income of $31.5 million for Q3 2025, compared to $9.9 million in Q3 2024, reflecting a 217.4% increase[22] - Net income for the three months ended September 30, 2025, was $31,507, compared to $9,335 for the same period in 2024, representing a year-over-year increase of 237%[70] - The effective tax rate for the three months ended September 30, 2025, was 27.5%, a decrease from 40.1% in the same period of 2024[173] Assets and Liabilities - Total current assets increased to $613.9 million as of September 30, 2025, compared to $482.3 million at the end of 2024, marking a 27.3% growth[16] - Total liabilities decreased to $1.33 billion as of September 30, 2025, down from $1.43 billion at the end of 2024, a reduction of 7.8%[16] - Cash and cash equivalents rose to $150.1 million as of September 30, 2025, compared to $70.6 million at the end of 2024, an increase of 112.5%[16] - Total assets measured at fair value as of September 30, 2025, amounted to $173,154 million, an increase from $130,344 million as of December 31, 2024[74] - The fair value of the Company's 2.875% convertible senior notes due in 2029 was $286,491 million with a net carrying value of $237,950 million as of September 30, 2025[78] Revenue Recognition and Accounting - The Company recognized revenue when a customer obtains control of promised goods, typically upon delivery, with payment received 30 to 90 days after[43] - The Company bases its estimates of variable consideration on historical data, including timing of rebates and returns, pricing adjustments, and quantity of products expected to be rebated or returned[45] - Provisions for product returns are based on product-level return rates and are estimated at the time of revenue recognition[47] - The Company provides an 18-month return window for customers, starting six months prior to expiration and ending twelve months after[48] - The Company disaggregates revenue from contracts with customers by product to reflect how economic factors affect revenue and cash flows[55] Acquisition and Intangible Assets - The Company closed its acquisition of Ironshore Therapeutics Inc. on September 3, 2024, acquiring the Jornay PM product, which has commercial approval in the U.S.[27] - The Ironshore Acquisition was completed on September 3, 2024, for a total consideration of approximately $306,104, which includes $276,888 in cash and $29,216 in deferred and contingent payments[62] - The fair value of acquired intangible assets from the Ironshore Acquisition was recorded at $635,000, amortized over a useful life of 7.7 years[65] - The total identifiable net assets acquired in the Ironshore Acquisition amounted to $294,036, with goodwill recorded at $12,068[64] Operating Expenses - Operating expenses for the nine months ended September 30, 2025, were $216.0 million, up from $147.3 million in the same period of 2024, a 46.7% increase[19] - Total commercial expenses for the three months ended September 30, 2025, were $36.93 million, up from $20.08 million in the same period of 2024, indicating an increase of 83.5%[177] - Selling, general and administrative expenses increased by $69.9 million to $217.2 million in the 2025 Period, primarily due to higher salaries and marketing expenses following the Ironshore Acquisition[210] - Salaries, wages, and benefits rose by $42.2 million, driven by additional headcount from the Ironshore Acquisition and executive transitions[210] - Sales and marketing expenses increased by $34.7 million to support the commercialization of Jornay PM post-Ironshore Acquisition[210] Stock and Shareholder Activities - The total shareholders' equity as of June 30, 2025, was $232.21 million, reflecting a net income of $31.51 million for the period[119] - The company repurchased shares under the Accelerated Share Repurchase agreement, resulting in a reduction of $25.01 million in treasury stock[119] - The company repurchased 2,704,830 shares at a weighted-average price of $31.43 per share, totaling $85,025 under the 2024-2025 Repurchase Program[127] - The 2025 Plan has 3,257,241 shares available for issuance as of September 30, 2025, with an aggregate of 1,600,000 shares authorized for issuance[121] - The company has not yet repurchased shares under the 2025-2026 Repurchase Program, leaving $150,000 available for share repurchases as of September 30, 2025[129] Legal Proceedings - The company is currently involved in multiple legal proceedings, including patent infringement lawsuits related to Xtampza ER and Nucynta, but is unable to estimate potential losses at this stage[146][150] - The company plans to vigorously defend against ongoing litigation, including the Merger Litigations related to the BDSI Acquisition, which allege violations of the Exchange Act[156][159] - The company has settled a patent infringement dispute with Aquestive Therapeutics for a one-time payment of $8,500, recognized as an expense in the consolidated statements of operations for the year ended December 31, 2023[155] - The company has received subpoenas related to opioid sales and marketing practices and is cooperating with investigations from several state Attorney General offices[151][152] Product Performance - Jornay PM generated $41,802 in revenue for the three months ended September 30, 2025, compared to $7,961 in the same period of 2024, reflecting a significant increase of 424%[56] - For the nine months ended September 30, 2025, product revenues were $575.1 million, a 27.9% increase from $449.5 million in the same period of 2024, driven by strong performance from Jornay PM and Nucynta Products[204] - Gross profit for the three months ended September 30, 2025, was $129.2 million, compared to $96.8 million in the same period of 2024, reflecting a gross margin improvement[189] - Jornay PM revenue increased by $33.8 million due to its acquisition from Ironshore Therapeutics in September 2024[191] - Nucynta Products revenue rose by $9.7 million, attributed to lower gross-to-net adjustments and higher gross prices, despite lower sales volume[192]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Financial Performance - Generated record quarterly net revenue of $209.4 million, up 31% year-over-year[1] - Generated record quarterly pain portfolio net revenue of $167.6 million, up 11% year-over-year, with all three core products growing year-over-year[5] - Generated Nucynta franchise net revenue of $54.8 million, up 21% year-over-year[8] - Adjusted EBITDA for Q3 2025 was $133.0 million, representing a 27% increase year-over-year[10] - GAAP net income for Q3 2025 was $31.5 million, with $1.00 GAAP earnings per share (basic)[9] - Net income for Q3 2025 was $31.5 million, significantly up from $9.3 million in Q3 2024, marking a 237.5% increase[28] - Adjusted EBITDA for Q3 2025 was $133.0 million, compared to $105.1 million in Q3 2024, representing a 26.5% increase[30] - The company reported a basic earnings per share of $1.00 for Q3 2025, compared to $0.29 for Q3 2024, reflecting a significant increase[28] Revenue Guidance - Raised full-year 2025 net revenue guidance to a range of $775 to $785 million and adjusted EBITDA guidance to a range of $460 to $470 million[1][6] - Collegium Pharmaceutical anticipates continued growth in product revenues and adjusted EBITDA for 2025, driven by market expansion and new product launches[1] Cash and Assets - Ended Q3'25 with cash, cash equivalents, and marketable securities of $285.9 million[1] - Total assets as of September 30, 2025, were $1.607 billion, a decrease from $1.664 billion as of December 31, 2024[26] - Cash and cash equivalents increased to $150.1 million from $70.6 million at the end of 2024, showing a 112.5% increase[26] Operating Expenses - Adjusted operating expenses for Q3 2025 were $55.7 million, representing a 60% increase year-over-year[9] - Selling, general and administrative expenses for Q3 2025 were $67.1 million, up from $62.0 million in Q3 2024, indicating an 8.5% increase[28] Product Performance - Generated record quarterly Jornay PM® net revenue of $41.8 million, with prescriptions growing by 20% year-over-year[5] - Jornay PM prescribers reached an all-time high of 27,700 healthcare providers, up 22% year-over-year[5] - Product revenues for Q3 2025 reached $209.4 million, a 31.5% increase from $159.3 million in Q3 2024[28] - Gross profit for Q3 2025 was $129.2 million, compared to $96.8 million in Q3 2024, reflecting a 33.4% year-over-year growth[28] Strategic Focus - The company is focused on managing relationships with licensors and maintaining regulatory approvals to support future growth[1]

Core Insights - Collegium Pharmaceutical, Inc. reported record quarterly net revenue of $209.4 million, representing a 31% increase year-over-year [1][11] - The company raised its full-year 2025 net revenue guidance to a range of $775 to $785 million and adjusted EBITDA guidance to a range of $460 to $470 million [1][8] - The company ended Q3 2025 with cash, cash equivalents, and marketable securities totaling $285.9 million [1] ADHD Business Highlights - Jornay PM net revenue reached a record $41.8 million, with prescriptions growing by 20% year-over-year [1][7] - The number of healthcare providers prescribing Jornay PM increased by 22% year-over-year, reaching an all-time high of 27,700 [7] Pain Portfolio Highlights - The pain portfolio generated record net revenue of $167.6 million, up 11% year-over-year, with all three core products showing growth [1][7] - Belbuca net revenue was $58.3 million, up 10% year-over-year, while Xtampza ER net revenue was $50.5 million, up 2% year-over-year [7] - Nucynta Franchise net revenue increased by 21% year-over-year, totaling $54.8 million [7] Financial Results - GAAP net income for Q3 2025 was $31.5 million, with GAAP earnings per share of $1.00 (basic) and $0.84 (diluted) [11][29] - Adjusted EBITDA for the quarter was $133.0 million, a 27% increase from the previous year [11][32] - The company generated $78.4 million in cash from operations during the quarter [11] Corporate Updates - The company has authorized a new share repurchase program to buy back up to $150 million of common stock through December 31, 2026 [10] - Collegium celebrated its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market [10]